CA
PASG icon

Clearstead Advisors’s Passage Bio PASG Stock Holding History

Clearstead Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4
Closed -$71 – 1550
2023
Q2 		$71 Hold
4
– – ﹤0.01% 1355
2023
Q1 		$72 Hold
4
– – ﹤0.01% 1357
2022
Q4 		$104 Hold
4
– – ﹤0.01% 1287
2022
Q3 		$0 Hold
4
– – ﹤0.01% 1330
2022
Q2 		$0 Hold
4
– – ﹤0.01% 1394
2022
Q1 		$0 Hold
4
– – ﹤0.01% 1439
2021
Q4 		$0 Hold
4
– – ﹤0.01% 1392
2021
Q3 		$1K Hold
4
– – ﹤0.01% 1230
2021
Q2 		$1K Buy
+4
New +$1.24K ﹤0.01% 1179

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Clearstead Advisors's PASG Position: Q3 2023 in Review

Clearstead Advisors sold out of Passage Bio (PASG) in Q3 2023, closing a stake of 4 shares — an estimated $71 sold.

Clearstead Advisors first reported a position in PASG in Q2 2021 and held it in 9 quarters. The position peaked at $1K in Q3 2021. 48 funds tracked by Wall St. Rank hold PASG as of Q3 2023.

  • Clearstead Advisors reported no remaining Passage Bio position as of Q3 2023 after selling out during the quarter.
  • Clearstead Advisors sold 4 Passage Bio shares in Q3 2023, an estimated $71.
  • Clearstead Advisors first reported a position in Passage Bio in Q2 2021 and held it in 9 quarters.
  • Clearstead Advisors's Passage Bio position peaked at $1K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Passage Bio as of Q3 2023.

Based on Clearstead Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.